MX2022005566A - Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. - Google Patents

Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.

Info

Publication number
MX2022005566A
MX2022005566A MX2022005566A MX2022005566A MX2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A MX 2022005566 A MX2022005566 A MX 2022005566A
Authority
MX
Mexico
Prior art keywords
hetero
pairing
igg molecules
charge pair
pair mutations
Prior art date
Application number
MX2022005566A
Other languages
English (en)
Inventor
Mark Daris
Zhulun Wang
Bram Estes
Fernando Garces
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2022005566A publication Critical patent/MX2022005566A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Abstract

La presente invención se refiere a heterodímeros que comprenden dominios CH3 de anticuerpos y mutilaciones útiles para facilitar la formación de heterodímeros. También se desvelan métodos para optimizar la purificación de los heterodímeros a determinados pH.
MX2022005566A 2019-11-08 2020-11-06 Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg. MX2022005566A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962933205P 2019-11-08 2019-11-08
PCT/US2020/059378 WO2021092355A1 (en) 2019-11-08 2020-11-06 Engineering charge pair mutations for pairing of hetero-igg molecules

Publications (1)

Publication Number Publication Date
MX2022005566A true MX2022005566A (es) 2022-07-19

Family

ID=73740489

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022005566A MX2022005566A (es) 2019-11-08 2020-11-06 Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.

Country Status (7)

Country Link
US (1) US20220389119A1 (es)
EP (1) EP4055060A1 (es)
JP (1) JP2022553813A (es)
AU (1) AU2020380379A1 (es)
CA (1) CA3160482A1 (es)
MX (1) MX2022005566A (es)
WO (1) WO2021092355A1 (es)

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
ATE135397T1 (de) 1988-09-23 1996-03-15 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005183A1 (en) 1988-10-31 1990-05-17 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ES2108048T3 (es) 1990-08-29 1997-12-16 Genpharm Int Produccion y utilizacion de animales inferiores transgenicos capaces de producir anticuerpos heterologos.
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
DE69224906T2 (de) 1991-07-08 1998-10-29 Univ Massachusetts Thermotropes flüssig-kristallines segment-blockcopolymer
ATE297465T1 (de) 1991-11-25 2005-06-15 Enzon Inc Verfahren zur herstellung von multivalenten antigenbindenden proteinen
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
WO2007109254A2 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
CA2680564C (en) 2007-03-12 2018-05-01 Esbatech Ag Sequence based engineering and optimization of single chain antibodies
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
WO2009000099A2 (en) 2007-06-25 2008-12-31 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
JP6351572B2 (ja) * 2012-05-10 2018-07-04 ザイムワークス，インコーポレイテッド Ｆｃドメインに突然変異を有する免疫グロブリン重鎖のヘテロ多量体構築物
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
EP3661954B1 (en) * 2017-08-03 2022-02-09 Amgen Inc. Interleukin-21 muteins and methods of treatment
CR20210319A (es) * 2018-01-12 2021-07-27 Amgen Inc ANTICUERPOS ANTI-PD-1 Y MÉTODOS DE TRATAMIENTO (Div. 2020-330)

Also Published As

Publication number Publication date
EP4055060A1 (en) 2022-09-14
AU2020380379A1 (en) 2022-05-26
WO2021092355A1 (en) 2021-05-14
JP2022553813A (ja) 2022-12-26
US20220389119A1 (en) 2022-12-08
CA3160482A1 (en) 2021-05-14

Similar Documents

Publication Publication Date Title
PH12019502283A1 (en) Anti-lag3 antibodies
MX2019014576A (es) Anticuerpos multiespecíficos manipulados genéticamente y otras proteínas multiméricas con mutaciones asimétricas en la región ch2-ch3.
EA201992670A1 (ru) Способ получения биспецифических антител, биспецифические антитела и терапевтическое применение таких антител
PH12021550337A1 (en) Anti-gdf15 antibodies, compositions and methods of use
MX2022009875A (es) Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
NZ739028A (en) Humanized or chimeric cd3 antibodies
MY174740A (en) Anti-il-33 antibodies and uses thereof
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
MX2021015888A (es) Fusión de un anticuerpo que se une a cea y 4-1bbl.
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
EA201890038A1 (ru) Антитела, которые связываются с сортилином и подавляют связывание програнулина
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
EA202091557A1 (ru) Антитела, содержащие только тяжелые цепи, которые связываются с cd22
CL2016001028A1 (es) Anticuerpos de alta afinidad y de agregación estable basados en dominios variables de vl y derivados de vhh.
EA201992206A1 (ru) Моноклональное антитело к pd-l1
MX2015016054A (es) Terapia de combinacion anti-quimiocina del ligando 2 del motif c-c y anti-lisil oxidasa-tipo 2 para el tratamiento de escleroderma.
MX2019011585A (es) Anticuerpos miltiespecificos estables.
EA201892440A1 (ru) Антитела к tl1a и их применения
MX2020007880A (es) Anticuerpos de mica/b y metodos de uso.
EA201992688A1 (ru) Средства, пути применения и способы лечения
NZ730186A (en) Humanized anti-hepcidin antibodies and uses thereof
EA202090513A1 (ru) Агенты, модулирующие функции бета-катенина, и связанные способы
MX2022005566A (es) Genomanipulación de mutaciones de par de carga para el emparejamiento de moléculas hetero-lgg.
PH12021550232A1 (en) Anti-mica/b antibodies that block mica/b shedding and methods of use
MX2021007421A (es) Anticuerpo que se une a factor de crecimiento endotelial vascular (vegf) y a interleucina 1 beta (il-1beta) y metodos de uso.